Cantor Fitzgerald Comments on Marinus Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities researchers at Cantor Fitzgerald cut their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a report issued on Tuesday, April 16th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn ($2.32) per share for the year, down from their prior estimate of ($2.13). Cantor Fitzgerald has a “Overweight” rating and a $28.00 price target on the stock. The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.37) per share.

Several other analysts have also recently weighed in on the company. Oppenheimer reaffirmed a “market perform” rating and issued a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Royal Bank of Canada reiterated a “sector perform” rating and set a $3.00 price objective (down from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday. Robert W. Baird reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday. StockNews.com lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $18.21.

Marinus Pharmaceuticals Stock Performance

NASDAQ:MRNS opened at $1.44 on Thursday. The business’s 50-day moving average price is $8.72 and its two-hundred day moving average price is $8.45. Marinus Pharmaceuticals has a twelve month low of $1.11 and a twelve month high of $11.26. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The business had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $7.78 million. During the same period in the previous year, the business earned ($0.76) EPS.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Nuveen Asset Management LLC grew its position in Marinus Pharmaceuticals by 1.1% during the 4th quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock worth $1,519,000 after acquiring an additional 1,475 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Marinus Pharmaceuticals by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after acquiring an additional 2,281 shares during the last quarter. Deutsche Bank AG grew its position in Marinus Pharmaceuticals by 14.7% during the 3rd quarter. Deutsche Bank AG now owns 25,961 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 3,321 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Marinus Pharmaceuticals by 94.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 7,541 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 3,661 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Marinus Pharmaceuticals by 5.7% in the 3rd quarter. Rhumbline Advisers now owns 70,705 shares of the biopharmaceutical company’s stock worth $569,000 after buying an additional 3,803 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.